Tumor blood vessels are a key target for cancer therapeutic management. Tumor cells
secrete high levels of pro-angiogenic factors which contribute to the creation of an abnormal …

The effectiveness of anticancer drugs in treating a solid tumour is dependent on delivery of
the drug to virtually all cancer cells in the tumour. The distribution of drug in tumour tissue …

Despite having an abundant number of vessels, tumours are usually hypoxic and nutrient-
deprived because their vessels malfunction. Such abnormal milieu can fuel disease …

New vessel formation (angiogenesis) is an essential physiological process for embryologic
development, normal growth, and tissue repair. Angiogenesis is tightly regulated at the …

Immunotherapy holds great promise for treating cancer. Nonetheless, T cell-based
immunotherapy of solid tumors has remained challenging, largely due to the lack of …

Classical chemotherapeutic anti-cancer treatments induce cell death through DNA damage
by taking advantage of the proliferative behaviour of cancer cells. The more recent approach …

Addition of multiple molecularly targeted agents to the existing armamentarium of
chemotherapeutics and radiotherapies represents a significant advance in the management …

Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and
immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) …

Various factors and cellular components in the tumor microenvironment are key drivers
associated with drug resistance in many cancers. Here, we analyzed the factors and …

Tumor vessels are characterized by abnormal morphology and hyperpermeability that
together cause inefficient delivery of chemotherapeutic agents. Although vascular …